MedTrace Logo

GSK1349572 Drug Interaction Study With Protease Inhibitors

NCT00774735 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-09-13

No results posted yet for this study

Summary

A study in healthy volunteers to determine whether there is a drug interaction between GSK1349572 and the HIV protease inhibitors lopinavir/ritonavir and darunavir/ritonavir

Conditions

  • Healthy Subjects
  • Infection, Human Immunodeficiency Virus

Interventions

DRUG

GSK1349572

30 mg given in combination with lopinavir/ritonavir

DRUG

GSK1349572

30 mg in combination with darunavir/ritonavir

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00774735 on ClinicalTrials.gov